Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial.
- DOI
- 10.1016/s2665-9913(19)30066-9
- Published
- 2019 Nov
- Container
- The Lancet. Rheumatology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2665-9913-19-30066-9,
title = {Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial.},
author = {Verhoef LM and den Broeder N and Thurlings RM and van der Laan WH and van der Weele W and Kok MR and Bernelot Moens HJ and Woodworth TG and van den Bemt BJF and van den Hoogen FHJ and den Broeder AA},
year = {2019},
journal = {The Lancet. Rheumatology},
doi = {10.1016/s2665-9913(19)30066-9},
url = {https://doi.org/10.1016/s2665-9913(19)30066-9}
}RIS
TY - JOUR TI - Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial. AU - Verhoef LM AU - den Broeder N AU - Thurlings RM AU - van der Laan WH AU - van der Weele W AU - Kok MR AU - Bernelot Moens HJ AU - Woodworth TG AU - van den Bemt BJF AU - van den Hoogen FHJ AU - den Broeder AA PY - 2019 JO - The Lancet. Rheumatology DO - 10.1016/s2665-9913(19)30066-9 UR - https://doi.org/10.1016/s2665-9913(19)30066-9 ER -
APA
LM, V., N, D. B., RM, T., WH, V. D. L., W, V. D. W., MR, K., HJ, B. M., TG, W., BJF, V. D. B., FHJ, V. D. H., & AA, D. B. (2019). Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial.. The Lancet. Rheumatology. https://doi.org/10.1016/s2665-9913(19)30066-9
Source records
- pubmed · retrieved 2026-09-26T21:53:51.637Z